In addition, 18.3% of the cases tested by NGS carried tumor-mutations in non-EGFR genes classified currently as non-actionable, such as TP53, SMAD4, FBXW7, CTNNB1 and NOTCH1. However, pathogenic variants in these genes were considered to have prognostic or predictive significances for NSCLC patients [21, 22]. The gene discussed is SMAD4; the disease is non-small cell lung carcinoma.